Keith Fandrick, Ph.D. is the Chief Operating Officer for OrphAI Therapeutics. Dr. Fandrick graduated with his Ph.D. in Chemistry from Harvard under the guidance of Professor David Evans where he worked on novel asymmetric methodologies and asymmetric synthesis of complex natural products. After graduation he joined the Chemical Development group at Boehringer Ingelheim where he was charged with the development of safe, economical and robust asymmetric synthesis of challenging compounds. His background and experience also include computational modeling with Quantum Mechanical/Density Function Theory. Dr. Fandrick has over 70 publications and patents.
